DK0658113T3 - Isoleret nonapeptid afledt af MAGE-3-gen og præsenteret af HLA-A1, og anvendelse deraf - Google Patents

Isoleret nonapeptid afledt af MAGE-3-gen og præsenteret af HLA-A1, og anvendelse deraf

Info

Publication number
DK0658113T3
DK0658113T3 DK93920419T DK93920419T DK0658113T3 DK 0658113 T3 DK0658113 T3 DK 0658113T3 DK 93920419 T DK93920419 T DK 93920419T DK 93920419 T DK93920419 T DK 93920419T DK 0658113 T3 DK0658113 T3 DK 0658113T3
Authority
DK
Denmark
Prior art keywords
hla
presented
mage
gene
derived
Prior art date
Application number
DK93920419T
Other languages
English (en)
Inventor
Christophe Lurquin
Catia Traversari
Der Bruggen Pierre Van
Plaen Etienne De
Thierry Boon-Falleur
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/938,334 external-priority patent/US5405940A/en
Priority claimed from US08/037,230 external-priority patent/US6235525B1/en
Priority claimed from US08/073,103 external-priority patent/US5462871A/en
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of DK0658113T3 publication Critical patent/DK0658113T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK93920419T 1992-08-31 1993-08-30 Isoleret nonapeptid afledt af MAGE-3-gen og præsenteret af HLA-A1, og anvendelse deraf DK0658113T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US07/938,334 US5405940A (en) 1992-08-31 1992-08-31 Isolated nonapeptides derived from MAGE genes and uses thereof
US08/037,230 US6235525B1 (en) 1991-05-23 1993-03-26 Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US08/073,103 US5462871A (en) 1992-08-31 1993-06-07 Isolated nucleic acid molecules which encode MAGE derived nonapeptides
PCT/US1993/008157 WO1994005304A1 (en) 1992-08-31 1993-08-30 Isolated nonapeptide derived from mage-3 gene and presented by hla-a1, and uses thereof

Publications (1)

Publication Number Publication Date
DK0658113T3 true DK0658113T3 (da) 2005-02-14

Family

ID=26713936

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93920419T DK0658113T3 (da) 1992-08-31 1993-08-30 Isoleret nonapeptid afledt af MAGE-3-gen og præsenteret af HLA-A1, og anvendelse deraf

Country Status (12)

Country Link
US (2) US6379901B1 (da)
EP (1) EP0658113B1 (da)
JP (1) JP3608788B2 (da)
AT (2) ATE280180T1 (da)
AU (1) AU668772B2 (da)
CA (1) CA2143335C (da)
DE (1) DE69333670T2 (da)
DK (1) DK0658113T3 (da)
ES (1) ES2225824T3 (da)
FI (1) FI950887A0 (da)
PT (1) PT658113E (da)
WO (1) WO1994005304A1 (da)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US20020168374A1 (en) * 1992-08-07 2002-11-14 Ralph T. Kubo Hla binding peptides and their uses
US5662907A (en) * 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
US6222012B1 (en) * 1992-08-31 2001-04-24 Ludwig Institute For Cancer Research Isolated nonapeptides presented by HLA molecules, and uses thereof
US6060257A (en) * 1994-06-03 2000-05-09 Ludwig Institute For Cancer Research Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof
US5977300A (en) * 1994-06-03 1999-11-02 Ludwig Institute Of Cancer Research Isolated nonapeptide which bind to HLA-B44 molecules and the uses thereof
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US5843648A (en) * 1995-01-10 1998-12-01 The United States Of America As Represented By The Secretary, Department Of Health And Human Services P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
US5587289A (en) * 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
CA2211448A1 (en) * 1995-03-21 1996-09-26 Ludwig Institute For Cancer Research Rage tumor rejection antigens
AU6283496A (en) * 1995-06-29 1997-01-30 Ludwig Institute For Cancer Research Isolated nucleic acid molecule which encodes murine tumor rejection antigen precursor smage-3
US7501501B2 (en) 1995-09-26 2009-03-10 The United States Of America As Represented By The Secretary Department Of Health And Human Services MHC-Class II restricted melanoma antigens and their use in therapeutic methods
US6951917B1 (en) 1995-09-26 2005-10-04 The United States Of America As Represented By The Department Of Health And Human Services MHC-class II restricted melanoma antigens and their use in therapeutic methods
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
US5965535A (en) * 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
CZ298364B6 (cs) 1998-02-05 2007-09-05 Smithkline Beecham Biologicals S. A. Deriváty antigenu asociovaných s nádory z MAGE rodiny a sekvence nukleových kyselin kodující tyto deriváty, jejich použití pro prípravu fúzních proteinu a prostredku pro vakcinaci
AU5810201A (en) 2000-05-10 2001-11-20 Aventis Pasteur Immunogenic polypeptides encoded by mage minigenes and uses thereof
EP1356048A2 (en) 2000-12-04 2003-10-29 Argonex Pharmaceuticals Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7405077B2 (en) * 2001-02-26 2008-07-29 Albany Medical College Sperm protein 17 for the diagnosis and treatment of cancer
JP4541645B2 (ja) 2001-04-12 2010-09-08 インペリアル・イノベイションズ・リミテッド Ｉ型癌の診断および治療
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
AU2004280608B2 (en) * 2002-04-09 2012-04-05 Sanofi Pasteur, Inc. Modified CEA/B7 vector
EP1496939B1 (en) 2002-04-09 2007-08-15 Sanofi Pasteur Limited Modified cea nucleic acid and expression vectors
US20040223949A1 (en) * 2002-10-22 2004-11-11 Sunnybrook And Women's College Health Sciences Center Aventis Pasteur, Ltd. Vaccines using high-dose cytokines
ES2633389T3 (es) 2003-01-30 2017-09-21 Survac Aps Péptidos derivados de survivina y uso de los mismos
PL2087904T3 (pl) 2003-11-19 2014-01-31 Survac Aps Zastosowanie terapeutyczne peptydów pochodzących z białek BcL-XL u pacjentów z rakiem
US7338670B2 (en) 2005-04-14 2008-03-04 Duke University Use of an agent that restores tissue perfusion and oxygenation
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
AR060358A1 (es) 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
JP2011506560A (ja) 2007-12-20 2011-03-03 ノバルティス アーゲー Ｐｉ３キナーゼ阻害剤として用いられるチアゾール誘導体
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
CA2786294A1 (en) 2010-02-22 2011-08-25 F. Hoffmann-La Roche Ag Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
US8987257B2 (en) 2011-01-31 2015-03-24 Novartis Ag Heterocyclic derivatives
CA2848209C (en) * 2011-09-15 2021-06-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
EP2771342B1 (en) 2011-10-28 2016-05-18 Novartis AG Purine derivatives and their use in the treatment of disease
GB201120860D0 (en) 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy
US10213432B2 (en) 2012-05-16 2019-02-26 Novartis Ag Dosage regimen for a PI-3 kinase inhibitor
PL3076969T3 (pl) 2013-12-06 2022-01-17 Novartis Ag Schemat dawkowania selektywnego inhibitora 3-kinazy fosfatydynozytolu alfa-izoformy
WO2016094309A1 (en) 2014-12-10 2016-06-16 Myosotis Inhibition of tnf signaling in cancer immunotherapy
JP2018521983A (ja) 2015-07-16 2018-08-09 バイオカイン セラピューティックス リミテッド がんを治療するための組成物および方法
GB201519340D0 (en) 2015-11-02 2015-12-16 Cambridge Entpr Ltd Methods of T-lymphocyte expansion
CA3002954A1 (en) 2015-11-02 2017-05-11 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
GB201519481D0 (en) 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
GB201616238D0 (en) 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
EP3565579B9 (en) 2017-01-05 2023-10-04 KAHR Medical Ltd. A pd1-41bbl fusion protein and methods of use thereof
JP7194324B2 (ja) 2017-01-05 2022-12-22 カール メディカル リミテッド ＳＩＲＰα－４１ＢＢＬ融合タンパク質およびその使用方法
GB201700345D0 (en) 2017-01-09 2017-02-22 F-Star Beta Ltd Conditional agonists of immune responses
IL250916A0 (en) 2017-03-02 2017-06-29 Geiger Benjamin Methods for growing t cells in culture and their use
WO2019006003A1 (en) 2017-06-27 2019-01-03 The Trustees Of Princeton University COMPOSITIONS AND METHODS FOR IMPROVING IMMUNOTHERAPY
GB201713078D0 (en) 2017-08-15 2017-09-27 Adaptimmune Ltd T Cell Modification
CN111836635A (zh) 2018-01-26 2020-10-27 剑桥企业有限公司 肽交换蛋白
CN112543773A (zh) 2018-07-11 2021-03-23 卡尔医学有限公司 SIRPα-4-1BBL变体融合蛋白及其使用方法
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
WO2020041662A1 (en) 2018-08-24 2020-02-27 The Trustees Of Princeton University Immunotherapy with metabolic enzyme expression
GB201820444D0 (en) 2018-12-14 2019-01-30 Adaptimmune Ltd Marker for T cell expansion
CA3146248A1 (en) 2019-07-11 2021-01-14 Kahr Medical Ltd. Heterodimers and methods of use thereof
GB201911954D0 (en) 2019-08-20 2019-10-02 Adaptimmune Ltd Lentiviral transduction methods
WO2021137231A1 (en) 2019-12-31 2021-07-08 Kahr Medical Ltd. Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same
US20230048361A1 (en) 2019-12-31 2023-02-16 Kahr Medical Ltd. Methods of culturing t cells and uses of same
IL276599A (en) 2020-08-09 2022-03-01 Yeda Res & Dev T cell receptor unique to mage-a1 and its uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4492760A (en) * 1983-04-19 1985-01-08 The Wistar Institute Of Anatomy And Biology HLA D Typing assay
US4707438A (en) * 1984-08-22 1987-11-17 Tel Aviv University Immunoassay for breast cancer employing monoclonal antibodies
WO1989007146A1 (en) * 1988-02-05 1989-08-10 Integrated Genetics, Inc. Rearranged tissue plasminogen activators and method for producing same
WO1992002543A1 (en) * 1990-08-01 1992-02-20 Cytel Corporation Novel immunosuppressant peptides
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
CA2141960A1 (en) * 1992-08-07 1994-02-17 Ralph T. Kubo Hla binding peptides and their uses
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof

Also Published As

Publication number Publication date
CA2143335C (en) 2000-03-14
CA2143335A1 (en) 1994-03-17
EP0658113A4 (en) 1997-11-26
DE69333670T2 (de) 2005-03-10
FI950887A (fi) 1995-02-27
WO1994005304A1 (en) 1994-03-17
ATE280180T1 (de) 2004-11-15
AU5096993A (en) 1994-03-29
US5695994A (en) 1997-12-09
JP3608788B2 (ja) 2005-01-12
EP0658113A1 (en) 1995-06-21
JPH08500837A (ja) 1996-01-30
US6379901B1 (en) 2002-04-30
FI950887A0 (fi) 1995-02-27
PT658113E (pt) 2005-03-31
EP0658113B1 (en) 2004-10-20
ES2225824T3 (es) 2005-03-16
DE69333670D1 (de) 2004-11-25
AU668772B2 (en) 1996-05-16
ATE378406T1 (de) 2007-11-15

Similar Documents

Publication Publication Date Title
DK0658113T3 (da) Isoleret nonapeptid afledt af MAGE-3-gen og præsenteret af HLA-A1, og anvendelse deraf
NO950660L (no) Isolert nonapeptid avledet fra MAGE-3-gen og presentert ved hjelp av HLA-Al, samt anvendelse derav
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
NO934130D0 (no) Tumoravvisningsantigenforl!pere, tumoravvisningsantigenersamt anvendelse derav
DE3751585T2 (de) Hybridome, die monoklonale Antikörper gegen neue Mucin-Epitope produzieren.
DK0810870T3 (da) Isolerede, MAGE-2-afledte tumorafstødelsesantigenpræcurserpeptider og anvendelse heraf
FI954536A0 (fi) Eristettyjä nukleiinihappomolekyylejä, jotka koodittavat kasvainhyljintäantigeenin esiastetta MAGE-3, ja niiden hyötykäyttö
HUP0000421A2 (hu) Retrovirális vektorok
DE69433790D1 (de) Isolierte peptide, die mit mhc mulekül hla-c-klon 10 komplexe bilden und ihre verwendungen
ATE258379T1 (de) Nukleinsäure, die für einen tumor abstossungsantigenvorläufer kodiert
DE69617440D1 (de) Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen
BR9707819A (pt) Imunogenos peptidicos
DE69511399T2 (de) Isolierte, von mage-3 abgeleitete peptide, welche mit hla-a2 molekülen komplexieren
NZ331398A (en) Tumor rejection antigens presented by hla-b44 molecules, and uses thereof
ATE60574T1 (de) Hydroxylierte 1,2-diamincyclohexan platinkomplexe.
NO20020329D0 (no) Antitumor antistoffer, proteiner og anvendelser derav
ATE209041T1 (de) Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendung
Williams Comments on" Structural Incongruities in Quaker Service"
Neagle Chile: President's Daughter Says Catholic Church Used Influence To Defeat Pinochet In Plebiscite
UA66753C2 (en) Immunostimulator and method for its production